Symposium - New York City, NY, United States
The biologics field remains a flourishing drug discovery and development area currently with over 200 products on the market, among which 35 monoclonal antibody therapeutics have been approved by the FDA and hundreds of candidates are in commercial development pipeline. Technology plays a pivotal role in developing next-generation biologics.For example, molecular engineering technologies have been successfully applied to optimize the drug attributes by modifying the molecular constitution of biologics. The recent US approval of the antibody-drug conjugate Kadcyla (also called T-DM1) for the treatment of breast cancer and Japan approval of glyco-engineered antibody mogamulizumab for T cell leukemia-lymphoma are two good examples. In addition, new technologies impact other aspects of biologics discovery and development such as manufacturing and delivery of drug substances.
Organization: New York Academy of Sciences
Hot Technologies for Developing Next-Gen Biologics
Tue, May 20, 2014 - Tue, May 20, 2014 (8:00 AM - 5:00 PM)
The New York Academy of Sciences
250 Greenwich St, 40th Floor, New York City, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
